Scraping the table, this video showcases various satisfying experiences, including ASMR sounds and visually pleasing moments. Enjoy a compilation of oddly satisfying clips that evoke a sense of ...

This is read by an automated voice. Please report any issues or inconsistencies here. ASMR, or autonomous sensory meridian response, is the calming tingling sensation brought on by gentle auditory, ...

ASMR has gained popularity over the past years for its potential effects on mood, cognition, and brain activity (Image: Canva) ASMR uses gentle sounds and movements to help people relax and reduce ...

O‑I Glass’ Fit to Win strategy is driving major cost reductions, lifting margins despite soft volumes in Europe and the Americas. Operating profit is up 63% YoY. Higher premiumization mix, faster new ...

Orion Innovation (“Orion”), a leading Data and AI–driven software engineering company, has announced the expansion of its Kochi operations with a larger, state-of-the-art facility and the launch of ...

- Phase 2 trial of adults with Osteogenesis Imperfecta (OI) is enrolling patients in the US and EU WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a ...

EDINBURGH, Scotland--(BUSINESS WIRE)--RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage ...

Ultragenyx Pharmaceutical Inc., is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases, announced results ...

Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone disease, setrusumab, failed a pair of phase 3 trials. The two partners said ...

The MarketWatch News Department was not involved in the creation of this content. Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo ...

Setrusumab did not meet primary fracture endpoints in the ORBIT and COSMIC trials but significantly improved bone mineral density in patients with osteogenesis imperfecta. Topline data were announced ...